赵立平团队:黄连素和二甲双胍应对肥胖?

黄连素和二甲双胍通过调节肠道菌群在临床中治疗二型糖尿病:
两种药物都可逆转高脂肪饮食引起的小鼠肠道菌群的改变;
两种药物都可显著降低肠道菌群多样性;
134种与肥胖表型相关的OTU受两种药物调控;
60种OTU会减少而产短链脂肪酸菌株会增加。
延伸阅读
Scientific Reports [IF:4.122]

Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats

黄连素和二甲双胍可调节肠道菌群,以应对小鼠因高脂饮食导致的肥胖

2015-09-23, Article, 10.1038/srep14405more

Abstract:
Accumulating evidence suggests that the gut microbiota is an important factor in mediating the development of obesity-related metabolic disorders, including type 2 diabetes. Metformin and berberine, two clinically effective drugs for treating diabetes, have recently been shown to exert their actions through modulating the gut microbiota. In this study, we demonstrated that metformin and berberine similarly shifted the overall structure of the gut microbiota in rats. Both drugs showed reverting effects on the high-fat diet-induced structural changes of gut microbiota. The diversity of gut microbiota was significantly reduced by both berberine- and metformin-treatments. Nearest shrunken centroids analysis identified 134 operational taxonomic units (OTUs) responding to the treatments, which showed close associations with the changes of obese phenotypes. Sixty out of the 134 OTUs were decreased by both drugs, while those belonging to putative short-chain fatty acids (SCFA)-producing bacteria, including Allobaculum, Bacteriodes, Blautia, Butyricoccus, and Phascolarctobacterium, were markedly increased by both berberine and, to a lesser extent, metformin. Taken together, our findings suggest that berberine and metformin showed similarity in modulating the gut microbiota, including the enrichment of SCFA-producing bacteria and reduction of microbial diversity, which may contribute to their beneficial effects to the host.

First Authors:
Xu Zhang

Correspondence Authors:
Liping Zhao

All Authors:
Xu Zhang,Yufeng Zhao,Jia Xu,Zhengsheng Xue,Menghui Zhang,Xiaoyan Pang,Xiaojun Zhang,Liping Zhao